
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/820699/publications.pdf Version: 2024-02-01



Ελειμα Κανιλιαι

#	Article	IF	CITATIONS
1	Underestimation of Cirrhosis-Related Mortality in the Medicare Eligible Population, 1999–2018. Clinical Gastroenterology and Hepatology, 2023, 21, 223-225.e3.	2.4	5
2	Risk factors for HCC in contemporary cohorts of patients with cirrhosis. Hepatology, 2023, 77, 997-1005.	3.6	36
3	Longâ€term outcomes and trends in liver transplantation for hereditary hemochromatosis in the United States. Liver Transplantation, 2023, 29, 15-25.	1.3	2
4	Conceptual Model for the Hepatocellular Carcinoma Screening Continuum: Current Status and Research Agenda. Clinical Gastroenterology and Hepatology, 2022, 20, 9-18.	2.4	58
5	Practical Consideration for Drug Monitoring of Tacrolimus in Liver Transplantation Recipients with SARS oVâ€2 Infection. Liver Transplantation, 2022, 28, 127-130.	1.3	1
6	Comparative performance of risk prediction models for hepatitis B-related hepatocellular carcinoma in the United States. Journal of Hepatology, 2022, 76, 294-301.	1.8	20
7	Clinical Factors Associated With Lack of Serological Response to SARSâ€CoVâ€2 Messenger RNA Vaccine in Liver Transplantation Recipients. Liver Transplantation, 2022, 28, 123-126.	1.3	25
8	Quality measures in HCC care by the Practice Metrics Committee of the American Association for the Study of Liver Diseases. Hepatology, 2022, 75, 1289-1299.	3.6	26
9	Effect of diabetes medications and glycemic control on risk of hepatocellular cancer in patients with nonalcoholic fatty liver disease. Hepatology, 2022, 75, 1420-1428.	3.6	65
10	Patientâ€reported outcomes in HCC: A scoping review by the Practice Metrics Committee of the American Association for the Study of Liver Diseases. Hepatology, 2022, 76, 251-274.	3.6	18
11	AASLD Practice Guidance: Palliative care and symptomâ€based management in decompensated cirrhosis. Hepatology, 2022, 76, 819-853.	3.6	56
12	Duration and cost-effectiveness of hepatocellular carcinoma surveillance in hepatitis C patients after viral eradication. Journal of Hepatology, 2022, 77, 55-62.	1.8	19
13	Significant improvements, but consistent disparities in survival for African Americans after liver transplantation. Clinical Transplantation, 2022, , e14646.	0.8	1
14	Comparable survival for hepatitis C-related hepatocellular carcinoma after liver transplantation irrespective of viremic status. Clinical Gastroenterology and Hepatology, 2022, , .	2.4	0
15	Reply. Clinical Gastroenterology and Hepatology, 2022, , .	2.4	0
16	Changing epidemiology of hepatocellular cancer in the United States: Winning the battle but it is not over yet. Hepatology, 2022, 76, 546-548.	3.6	4
17	Reply. Hepatology, 2022, 76, E50-E50.	3.6	0
18	Perceptions of weight status and energy balance behaviors among patients with non-alcoholic fatty liver disease. Scientific Reports, 2022, 12, 5695.	1.6	6

#	Article	IF	CITATIONS
19	Early Impact of MMaT-3 Policy on Liver Transplant Waitlist Outcomes for Hepatocellular Carcinoma. Transplantation Direct, 2022, 8, e1313.	0.8	10
20	Oral Health and the Altered Colonic Mucosa-Associated Gut Microbiota. Digestive Diseases and Sciences, 2021, 66, 2981-2991.	1.1	10
21	Validation of the Updated Hepatocellular Carcinoma Early Detection Screening Algorithm in a Community-Based Cohort of Patients With Cirrhosis of Multiple Etiologies. Clinical Gastroenterology and Hepatology, 2021, 19, 1443-1450.e6.	2.4	13
22	Incidence of Hepatocellular Carcinoma in Primary Biliary Cholangitis: A Systematic Review and Meta-Analysis. Digestive Diseases and Sciences, 2021, 66, 2439-2451.	1.1	23
23	Texas Has the Highest Hepatocellular Carcinoma Incidence Rates in the USA. Digestive Diseases and Sciences, 2021, 66, 912-916.	1.1	19
24	Women Have a Lower Risk of Nonalcoholic Fatty Liver Disease but a Higher Risk of Progression vs Men: A Systematic Review and Meta-analysis. Clinical Gastroenterology and Hepatology, 2021, 19, 61-71.e15.	2.4	159
25	Reply to: "The role of the model for end-stage liver disease sodium score and joint models for 90-day mortality prediction in in patients with acute-on-chronic liver failure― Journal of Hepatology, 2021, 74, 477.	1.8	0
26	Unconscious Bias in Peer Review. Clinical Gastroenterology and Hepatology, 2021, 19, 419-420.	2.4	13
27	Development of Quality Measures in Cirrhosis by the Practice Metrics Committee of the American Association for the Study of Liver Diseases. Clinical Liver Disease, 2021, 17, 308-308.	1.0	Ο
28	On the Proposed Definition of Metabolic-Associated Fatty Liver Disease. Clinical Gastroenterology and Hepatology, 2021, 19, 865-870.	2.4	33
29	Outcomes in the Era of Interferon-Free Direct-Acting Antiviral Therapy After Liver Transplantation in Patients with Hepatitis C Virus and Hepatocellular Carcinoma. Journal of Hepatocellular Carcinoma, 2021, Volume 8, 701-711.	1.8	1
30	Racial and ethnic disparities in non-alcoholic fatty liver disease in the USA. The Lancet Gastroenterology and Hepatology, 2021, 6, 422-424.	3.7	11
31	Reply. Clinical Gastroenterology and Hepatology, 2021, , .	2.4	Ο
32	Presentation of the AGA William Beaumont Prize in Gastroenterology to David Y. Graham, MD. Gastroenterology, 2021, 161, 333-335.	0.6	0
33	Preparing for the NASH Epidemic: A Call to Action. Diabetes Care, 2021, 44, 2162-2172.	4.3	30
34	Factors Associated With Access to and Receipt of Liver Transplantation in Veterans With End-stage Liver Disease. JAMA Internal Medicine, 2021, 181, 949.	2.6	35
35	Spatial Characteristics of Colonic Mucosa-Associated Gut Microbiota in Humans. Microbial Ecology, 2021, , 1.	1.4	10
36	NAFLD and HCC: Time to Bridge the Gap. Hepatology, 2021, 74, 2336-2338.	3.6	3

#	Article	IF	CITATIONS
37	Preparing for the NASH epidemic: A call to action. Obesity, 2021, 29, 1401-1412.	1.5	7
38	Preparing for the NASH Epidemic: A Call to Action. Gastroenterology, 2021, 161, 1030-1042.e8.	0.6	58
39	Elevated serum sodium in recipients of liver transplantation has a substantial impact on outcomes. Transplant International, 2021, 34, 1971-1983.	0.8	2
40	Impact of COVIDâ€19 Pandemic on Liver Transplantation and Alcoholâ€Associated Liver Disease in the USA. Hepatology, 2021, 74, 3316-3329.	3.6	75
41	Preparing for the NASH epidemic: A call to action. Metabolism: Clinical and Experimental, 2021, 122, 154822.	1.5	25
42	Clinical Care Pathway for the Risk Stratification and Management of Patients With Nonalcoholic Fatty Liver Disease. Gastroenterology, 2021, 161, 1657-1669.	0.6	229
43	Marginal Allografts in Liver Transplantation Have a Limited Impact on Length of Stay. Clinical Transplantation, 2021, , e14544.	0.8	1
44	Longâ€Term Risk of Hepatocellular Carcinoma in HCV Patients Treated With Direct Acting Antiviral Agents. Hepatology, 2020, 71, 44-55.	3.6	188
45	Integrated Model for Patient-Centered Advanced Liver Disease Care. Clinical Gastroenterology and Hepatology, 2020, 18, 1015-1024.	2.4	19
46	Effect of Metabolic Traits on the Risk of Cirrhosis and Hepatocellular Cancer in Nonalcoholic Fatty Liver Disease. Hepatology, 2020, 71, 808-819.	3.6	170
47	Effectiveness of Elbasvir/Grazoprevir in patients with hepatitis C virus genotype 1 infection and chronic kidney disease in the United States veterans population. Antiviral Research, 2020, 174, 104698.	1.9	10
48	Renal Trajectory Patterns Are Associated With Postdischarge Mortality in Patients With Cirrhosis and Acute Kidney Injury. Clinical Gastroenterology and Hepatology, 2020, 18, 1858-1866.e6.	2.4	11
49	Covering the Year in CGH: 2019. Clinical Gastroenterology and Hepatology, 2020, 18, 3-10.	2.4	3
50	The Influence of Gut and Tumor Microbiome on Pancreatic Cancer Outcomes. Gastroenterology, 2020, 159, 1184-1185.	0.6	2
51	Trends in Outcomes for Marginal Allografts in Liver Transplant. JAMA Surgery, 2020, 155, 926.	2.2	48
52	Reply to: "Model for end-stage liver disease-sodium in acute-on-chronic liver failure― Journal of Hepatology, 2020, 73, 1579-1580.	1.8	0
53	Model for end-stage liver disease-sodium underestimates 90-day mortality risk in patients with acute-on-chronic liver failure. Journal of Hepatology, 2020, 73, 1425-1433.	1.8	81
54	Aggressive utilization of liver allografts: Improved outcomes over time. Clinical Transplantation, 2020, 34, e13860.	0.8	1

#	Article	IF	CITATIONS
55	A learning curve in using orphan liver allografts for transplantation. Clinical Transplantation, 2020, 34, e13821.	0.8	0
56	Retrospective analysis of longâ€ŧerm outcome 10 years after liver transplantation for Wilson disease: experience over three decades. Transplant International, 2020, 33, 925-935.	0.8	3
57	Assessment of Incidence of and Surveillance Burden for Hepatocellular Carcinoma Among Patients With Hepatitis C in the Era of Direct-Acting Antiviral Agents. JAMA Network Open, 2020, 3, e2021173.	2.8	15
58	Development, Validation, and Evaluation of a Simple Machine Learning Model to Predict Cirrhosis Mortality. JAMA Network Open, 2020, 3, e2023780.	2.8	45
59	Risk Factors for Cirrhosis in Contemporary Hepatology Practices—Findings From the Texas Hepatocellular Carcinoma Consortium Cohort. Gastroenterology, 2020, 159, 376-377.	0.6	32
60	Early Impact of COVID-19 on Solid Organ Transplantation in the United States. Transplantation, 2020, 104, 2221-2224.	0.5	68
61	Clinical efficacy of direct-acting antiviral therapy for recurrent hepatitis C virus infection after liver transplantation in patients with hepatocellular carcinoma. World Journal of Hepatology, 2020, 12, 628-640.	0.8	2
62	The HCV Treatment Cascade: Race Is a Factor to Consider. Journal of General Internal Medicine, 2019, 34, 1949-1951.	1.3	5
63	Reply to: "Prevalence and short-term mortality in a national US cohort with acute-on-chronic liver failure― Journal of Hepatology, 2019, 71, 638-639.	1.8	1
64	Changes in hepatitis C burden and treatment trends in Europe during the era of direct-acting antivirals: a modelling study. BMJ Open, 2019, 9, e026726.	0.8	34
65	Risk Trajectories for Readmission and Death After Cirrhosis-Related Hospitalization. Digestive Diseases and Sciences, 2019, 64, 1470-1477.	1.1	3
66	AGA Clinical Practice Update on Interaction Between Oral Direct-Acting Antivirals for Chronic Hepatitis C Infection and Hepatocellular Carcinoma: Expert Review. Gastroenterology, 2019, 156, 2149-2157.	0.6	90
67	Reply to: "Mortality of acute-on-chronic liver failure: What is the role of obesity?― Journal of Hepatology, 2019, 70, 1301-1302.	1.8	Ο
68	Dietary Nutrients Involved in One-Carbon Metabolism and Colonic Mucosa-Associated Gut Microbiome in Individuals with an Endoscopically Normal Colon. Nutrients, 2019, 11, 613.	1.7	48
69	Design of the Texas Hepatocellular Carcinoma Consortium Cohort Study. American Journal of Gastroenterology, 2019, 114, 530-532.	0.2	27
70	Prevalence and short-term mortality of acute-on-chronic liver failure: A national cohort study from the USA. Journal of Hepatology, 2019, 70, 639-647.	1.8	101
71	Development of Quality Measures in Cirrhosis by the Practice Metrics Committee of the American Association for the Study of Liver Diseases. Hepatology, 2019, 69, 1787-1797.	3.6	92
72	Nutrition in Alcoholic Liver Disease. Clinics in Liver Disease, 2019, 23, 99-114.	1.0	18

#	Article	IF	CITATIONS
73	Awareness of chronic viral hepatitis in the United States: An update from the National Health and Nutrition Examination Survey. Journal of Viral Hepatitis, 2019, 26, 596-602.	1.0	67
74	Cost Effectiveness of Transplanting HCV-Infected Livers Into Uninfected Recipients With Preemptive Antiviral Therapy. Clinical Gastroenterology and Hepatology, 2019, 17, 739-747.e8.	2.4	24
75	Trends in Chronic Liver Disease-Related Hospitalizations: A Population-Based Study. American Journal of Gastroenterology, 2019, 114, 98-106.	0.2	36
76	Positive Predictive Value of International Classification of Diseases, 10th Revision, Codes for Cirrhosis and Its Related Complications. Clinical Gastroenterology and Hepatology, 2018, 16, 1677-1678.	2.4	63
77	Hepatology in a changing health care landscape: A call for health services research. Hepatology, 2018, 68, 1154-1162.	3.6	Ο
78	Patientâ€reported outcomes in cirrhosis: A scoping review of the literature. Hepatology, 2018, 67, 2375-2383.	3.6	62
79	Cost-effectiveness and Decision Analysis in Clinical Gastroenterology and Hepatology: From Evidence to Informed Decision Making. Clinical Gastroenterology and Hepatology, 2018, 16, 459-461.	2.4	3
80	Evaluating screening approaches for hepatocellular carcinoma in a cohort of HCV related cirrhosis patients from the Veteran's Affairs Health Care System. BMC Medical Research Methodology, 2018, 18, 1.	1.4	390
81	Houston Consensus Conference on Testing for Helicobacter pylori Infection in the United States. Clinical Gastroenterology and Hepatology, 2018, 16, 992-1002.e6.	2.4	189
82	Cost Effectiveness of Pre– vs Post–Liver Transplant Hepatitis C Treatment With Direct-Acting Antivirals. Clinical Gastroenterology and Hepatology, 2018, 16, 115-122.e10.	2.4	21
83	A Randomized Trial of Offâ€Site Collaborative Care for Depression in Chronic Hepatitis C Virus. Health Services Research, 2018, 53, 2547-2566.	1.0	8
84	Role of Age and Race in the Risk of Hepatocellular Carcinoma in Veterans With Hepatitis B Virus Infection. Clinical Gastroenterology and Hepatology, 2018, 16, 252-259.	2.4	47
85	Transplanting hepatitis C virus–positive livers into hepatitis C virus–negative patients with preemptive antiviral treatment: A modeling study. Hepatology, 2018, 67, 2085-2095.	3.6	50
86	Risk of Hepatocellular Cancer in Patients With Non-Alcoholic Fatty Liver Disease. Gastroenterology, 2018, 155, 1828-1837.e2.	0.6	490
87	Implementation of a Population-Based Cirrhosis Identification and Management System. Clinical Gastroenterology and Hepatology, 2018, 16, 1182-1186.e2.	2.4	11
88	Increasing Health Care Burden of Chronic Liver Disease Compared With Other Chronic Diseases, 2004–2013. Gastroenterology, 2018, 155, 719-729.e4.	0.6	81
89	Incidence and Determinants of Hepatocellular Carcinoma in Autoimmune Hepatitis: A Systematic Review and Meta-analysis. Clinical Gastroenterology and Hepatology, 2017, 15, 1207-1217.e4.	2.4	71
90	The Validity of HCC Diagnosis Codes in Chronic Hepatitis B Patients in the Veterans Health Administration. Digestive Diseases and Sciences, 2017, 62, 1180-1185.	1.1	8

FASIHA KANWAL

#	Article	IF	CITATIONS
91	NAFLD-Related HCC: How Should the Shift in Epidemiology Change Our Prevention and Surveillance Strategies?. Current Hepatology Reports, 2017, 16, 26-32.	0.4	0
92	Hepatitis C and Risk of Nonhepatic Malignancies. Clinics in Liver Disease, 2017, 21, 543-554.	1.0	15
93	The Top Five Reasons You Should Publish in Clinical Gastroenterology and Hepatology. Clinical Gastroenterology and Hepatology, 2017, 15, 164-165.	2.4	2
94	Reply to: "Inappropriate use of FIB-4 index for cirrhosis detection in hepatocellular carcinoma patients― Journal of Hepatology, 2017, 67, 884-885.	1.8	1
95	Reply to: "Hepatocellular carcinoma (HCC) in the absence of cirrhosis in patients with chronic hepatitis B virus infection― Journal of Hepatology, 2017, 67, 886-887.	1.8	1
96	Risk of Hepatocellular Cancer in HCV Patients Treated With Direct-Acting Antiviral Agents. Gastroenterology, 2017, 153, 996-1005.e1.	0.6	680
97	Global epidemiology and burden of HCV infection and HCV-related disease. Nature Reviews Gastroenterology and Hepatology, 2017, 14, 122-132.	8.2	317
98	Shiftwork Is Not Associated with Increased Risk of NAFLD: Findings from the National Health and Nutrition Examination Survey. Digestive Diseases and Sciences, 2017, 62, 526-533.	1.1	27
99	Anniversary Tribute From the Editors of Clinical Gastroenterology and Hepatology. Clinical Gastroenterology and Hepatology, 2017, 15, 1823-1827.	2.4	0
100	Accurate Identification of Fatty Liver Disease in Data Warehouse Utilizing Natural Language Processing. Digestive Diseases and Sciences, 2017, 62, 2713-2718.	1.1	28
101	Natural History of Untreated Hepatocellular Carcinoma in a US Cohort and the Role of Cancer Surveillance. Clinical Gastroenterology and Hepatology, 2017, 15, 273-281.e1.	2.4	106
102	Hepatocellular carcinoma in the absence of cirrhosis in patients with chronic hepatitis B virus infection. Journal of Hepatology, 2017, 66, 355-362.	1.8	104
103	Acculturation and Nonalcoholic Fatty Liver Disease Risk Among Hispanics of Mexican Origin: Findings From the National Health and Nutrition Examination Survey. Clinical Gastroenterology and Hepatology, 2017, 15, 310-312.	2.4	12
104	Incidence of Hepatocellular Carcinoma in All 50 United States, From 2000 Through 2012. Gastroenterology, 2017, 152, 812-820.e5.	0.6	339
105	Optimal timing of hepatitis C treatment for patients on the liver transplant waiting list. Hepatology, 2017, 65, 777-788.	3.6	83
106	Reply. Clinical Gastroenterology and Hepatology, 2016, 14, 487-488.	2.4	0
107	Quality of Care in the Cirrhotic Patient. Clinical and Translational Gastroenterology, 2016, 7, e166.	1.3	18
108	Race and Gender Differences in the Use of Direct Acting Antiviral Agents for Hepatitis C Virus. Clinical Infectious Diseases, 2016, 63, 291-299.	2.9	60

#	Article	IF	CITATIONS
109	Prediction Models for Gastrointestinal and Liver Diseases: Too Many Developed, Too Few Validated. Clinical Gastroenterology and Hepatology, 2016, 14, 1678-1680.	2.4	23
110	Collaborative Care for Depression in Chronic Hepatitis C Clinics. Psychiatric Services, 2016, 67, 1076-1082.	1.1	7
111	Statins Are Underutilized in Patients with Nonalcoholic Fatty Liver Disease and Dyslipidemia. Digestive Diseases and Sciences, 2016, 61, 1714-1720.	1.1	72
112	Efficacy of Psychosocial Interventions in Inducing and Maintaining Alcohol Abstinence in Patients With Chronic LiverÂDisease: A Systematic Review. Clinical Gastroenterology and Hepatology, 2016, 14, 191-202.e4.	2.4	126
113	Trends in the Burden of Nonalcoholic Fatty Liver Disease inÂaÂUnited States Cohort of Veterans. Clinical Gastroenterology and Hepatology, 2016, 14, 301-308.e2.	2.4	136
114	Hepatocellular Carcinoma in the Absence of Cirrhosis in United States Veterans Is Associated With Nonalcoholic Fatty Liver Disease. Clinical Gastroenterology and Hepatology, 2016, 14, 124-131.e1.	2.4	471
115	Genetic Variants in Interleukin-28B Are Associated with Diabetes and Diabetes-Related Complications in Patients with Chronic Hepatitis C Virus Infection. Digestive Diseases and Sciences, 2015, 60, 2030-2037.	1.1	3
116	Use of Hy's Law, R Criteria, and nR Criteria to Predict Acute Liver Failure or Transplantation in Patients With Drug-Induced Liver Injury. Gastroenterology, 2015, 148, 452.	0.6	3
117	Temporal Trends of Nonalcoholic Fatty Liver Disease–Related Hepatocellular Carcinoma in the Veteran Affairs Population. Clinical Gastroenterology and Hepatology, 2015, 13, 594-601.e1.	2.4	215
118	Nonalcoholic Fatty Liver Disease is Underrecognized in the Primary Care Setting. American Journal of Gastroenterology, 2015, 110, 10-14.	0.2	110
119	Pay for Performance in Chronic Liver Disease. Clinical Gastroenterology and Hepatology, 2015, 13, 2042-2047.	2.4	8
120	Response to Li et al American Journal of Gastroenterology, 2015, 110, 774.	0.2	0
121	Why We Should Be Willing to Pay for Hepatitis C Treatment. Clinical Gastroenterology and Hepatology, 2015, 13, 1711-1713.	2.4	10
122	Decreasing Mortality in Patients Hospitalized With Cirrhosis. Gastroenterology, 2015, 148, 897-900.	0.6	12
123	The Art and Science of Managing Liver Disease. Clinical Gastroenterology and Hepatology, 2015, 13, 2029-2030.	2.4	1
124	Clinical outcomes of hepatitis B virus coinfection in a United States cohort of hepatitis C virusâ€infected patients. Hepatology, 2014, 60, 1871-1878.	3.6	67
125	New Diagnosis of Chronic Pancreatitis: Risk of Missing an Underlying Pancreatic Cancer. American Journal of Gastroenterology, 2014, 109, 1824-1830.	0.2	52
126	Improving Quality of Health Care for Patients With Cirrhosis. Gastroenterology, 2014, 147, 1204-1207.	0.6	34

#	Article	IF	CITATIONS
127	The End of Hepatitis C. Clinical Gastroenterology and Hepatology, 2014, 12, 533-536.	2.4	26
128	Primary Prophylaxis of Variceal Bleeding. Gastroenterology Clinics of North America, 2014, 43, 783-794.	1.0	4
129	Racial Differences in the Progression to Cirrhosis and Hepatocellular Carcinoma in HCV-Infected Veterans. American Journal of Gastroenterology, 2014, 109, 1427-1435.	0.2	84
130	The Quality of Care Provided to Patients With Varices in the Department of Veterans Affairs. American Journal of Gastroenterology, 2014, 109, 934-940.	0.2	42
131	Hepatitis C Virus Treatment: The Unyielding Chasm Between Efficacy andÂEffectiveness. Clinical Gastroenterology and Hepatology, 2014, 12, 1381-1383.	2.4	16
132	Increased Risk of Pancreatic Adenocarcinoma After Acute Pancreatitis. Clinical Gastroenterology and Hepatology, 2014, 12, 1143-1150.e1.	2.4	85
133	A New Laboratory-Based Algorithm to Predict Development of Hepatocellular Carcinoma in Patients With Hepatitis C and Cirrhosis. Gastroenterology, 2014, 146, 1249-1255.e1.	0.6	156
134	Many Patients With Interleukin 28B Genotypes Associated With Response to Therapy Are Ineligible for Treatment Because of Comorbidities. Clinical Gastroenterology and Hepatology, 2014, 12, 327-333.e1.	2.4	11
135	Improving quality of care in patients with cirrhosis. Clinical Liver Disease, 2013, 2, 123-124.	1.0	5
136	Association Between Nonalcoholic Fatty Liver Disease and Risk for Hepatocellular Cancer, Based on Systematic Review. Clinical Gastroenterology and Hepatology, 2012, 10, 1342-1359.e2.	2.4	634
137	The Quality of Care Provided to Patients With Cirrhosis and Ascites in the Department of Veterans Affairs. Gastroenterology, 2012, 143, 70-77.	0.6	133
138	An Explicit Quality Indicator Set for Measurement of Quality of Care in Patients With Cirrhosis. Clinical Gastroenterology and Hepatology, 2010, 8, 709-717.	2.4	109